SRS309 - Implementation and evaluation of a two-week fast-track whipple pathway with integrated PET imaging for pancreatic cancer patients

View at publisher Summarise with VIRAT
Authors: Fatima Zulfiqar, Zaid Al-Sheikh Ali, Doaa Abdulaziz, Abduljalil Abiri, Hassan Elghonemy, Navneet Tiwari, Akshadhar J. Koneti, Dinesh Sharma, Giuseppe Fusai, Brian Ritchie Davidson, Charles J. Imber, Sakhanat Rahman
+5 more Satheesh Iype, Carlo D. L. Ceresa, David Nasralla, Stephanos Pericleous, David Wallace
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Pancreatic cancer has a 5-year survival rate of less than 10%. Approximately 15% of patients present with resectable disease at diagnosis. The narrow window of opportunity for curative intervention makes time a critical factor in pancreatic cancer management. This prospective cohort study assesses the impact of London’s first fast-track Whipple’s pathway since its introduction in September 2023. We evaluate its effectiveness in expediting surgical management for patients with suspected pancreatic cancer, with a target of achieving surgery within 15 days of referral for 90% of eligible patients. Forty-three patients were enrolled in the pathway, with a median age of 66 and an equal sex distribution. The median pre-operative bilirubin level was 189. The median interval from referral to FDG-PET was 7 days, and from referral to surgery was 12 days, a significant reduction compared to the traditional pathway. Thirty-eight patients (88.3%) successfully underwent pancreatic resection (28 standard Whipple’s procedures, 6 Whipple’s with portal vein resection, 3 total pancreatectomies, and 1 extrahepatic bile duct resection). Histopathological analysis revealed that 79% of cases were adenocarcinoma, 12% cholangiocarcinoma, and 7.6% comprised benign lesions, GIST, and metastatic lobular carcinoma. Clinical outcomes have been favourable, with 44% of patients achieving R0 resection and 15.7% presenting with N2 stage disease. Thirty-five patients (81%) experienced a good recovery at 30 days post-surgery. These results align with international literature on expedited pathways, reducing the need for preoperative biliary stenting and the inflammatory complications seen in the 60-day traditional pathway; this represents a cost-effective advantage warranting further comparative evaluation.

Fields of Study & Subjects

Pancreatic and Hepatic Oncology Research Enhanced Recovery After Surgery Lung Cancer Diagnosis and Treatment

Publication details

Journal / source
British journal of surgery
Volume
113
Issue
Supplement_2
Publication date
1 March 2026
Language
EN